

Overexpression of SDF-1 α Enhanced Migration and Engraftment of Cardiac Stem Cells and Reduced Infarcted Size via CXCR4/PI3K Pathway

Kui Wang¹, Xiaohui Zhao¹, Chunyan Kuang, Dehui Qian, Hang Wang, Hong Jiang, Mengyang Deng, Lan Huang*

Institute of Cardiovascular Diseases of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, People's Republic of China

Abstract

Cardiac stem cells (CSCs) can home to the infarcted area and regenerate myocardium. Stromal cell-derived factor-1 α /C-X-C chemokine receptor type 4 (SDF-1 α /CXCR4) axis is pivotal in inducing CSCs migration. However, the mechanisms remain unclear. This study set out to detect if SDF-1 α promotes migration and engraftment of CSCs through the CXCR4/PI3K (phosphatidylinositol 3-kinase) pathway. In the *in vitro* experiment, c-kit⁺ cells were isolated from neonatal mouse heart fragment culture by magnetic cell sorting. Fluorescence-activated cell sorting results demonstrated that a few c-kit⁺ cells expressed CD45 (4.54%) and Sca-1 (2.58%), the hematopoietic stem cell marker. Conditioned culture could induce c-kit⁺ cells multipotent differentiation, which was confirmed by cardiac troponin I (cTn-I), α -smooth muscle actin (α -SMA), and von Willebrand factor (vWF) staining. *In vitro* chemotaxis assays were performed using Transwell cell chambers to detect CSCs migration. The results showed that the cardiomyocytes infected with rAAV1-SDF-1 α -eGFP significantly increased SDF-1 α concentration, 5-fold more in supernatant than that in the control group, and subsequently attracted more CSCs migration. This effect was diminished by administration of AMD3100 (10 μ g/ml, CXCR4 antagonist) or LY294002 (20 μ mol/L, PI3K inhibitor). In myocardial infarction mice, overexpression of SDF-1 α in the infarcted area by rAAV1-SDF-1 α -eGFP infection resulted in more CSCs retention to the infarcted myocardium, a higher percentage of proliferation, and reduced infarcted area which was attenuated by AMD3100 or LY294002 pretreatment. These results indicated that overexpression of SDF-1 α enhanced CSCs migration *in vitro* and engraftment of transplanted CSCs and reduced infarcted size via CXCR4/PI3K pathway.

Citation: Wang K, Zhao X, Kuang C, Qian D, Wang H, et al. (2012) Overexpression of SDF-1 α Enhanced Migration and Engraftment of Cardiac Stem Cells and Reduced Infarcted Size via CXCR4/PI3K Pathway. PLoS ONE 7(9): e43922. doi:10.1371/journal.pone.0043922

Editor: Gangjian Qin, Northwestern University, United States of America

Received: March 9, 2012; **Accepted:** July 27, 2012; **Published:** September 11, 2012

Copyright: © 2012 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Grant from National Natural Science Foundation of China (30800480, <http://www.nsf.gov.cn/Portal0/default152.htm>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: zxhwn2002@yahoo.com.cn

These authors contributed equally to this work.

Introduction

Myocardial infarction (MI) is one of the leading causes of death and the ischemic injury is usually irreversible despite aggressive medical and revascularization treatment. Previous studies have shown that cardiac stem cells (CSCs) can differentiate into cardiomyocytes, smooth muscle cells or endothelial cells [1–4]. Therefore, transplantation of CSCs can reduce infarcted size and enhance heart function [1,5–7], representing a new strategy for cardiac repair. At present, a variety of CSCs have been reported and classified according to biological markers such as c-kit⁺, side population and Islet-1⁺ [3,8]. C-kit [9], also called KIT or CD117, is a cytokine receptor expressed on the surface of multiple stem cells. The c-kit⁺ CSCs represent one of the major CSCs populations which have properties of multidirectional differentiation [2,3]. Animal and human studies [10–15] indicate that transplantation of c-kit⁺ CSCs reduces infarcted size and improves cardiac function of MI. However, the mechanism of c-kit⁺ CSCs homing to the infarcted zone is not clear.

Migration is a critical process for stem cells recruitment into target area and tissue repairing. Up to now, stromal cell-derived factor-1 α (SDF-1 α) and its cellular receptor CXCR4 (C-X-C chemokine receptor type 4) are known as the most prominent stem cell chemotaxis. SDF-1 α has been shown to be significantly upregulated in many experimental models including myocardial infarction [5,16] and attract the CXCR4⁺ stem cells towards SDF-1 α gradient. Thus, upregulation of SDF-1 α expression in ischemic myocardium represents a promising therapeutic strategy to improve post-infarction therapy. Recently, Tang et al [17] reported that exogenously expressed vascular endothelial growth factor (VEGF) promoted myocardial repair at least in part through SDF-1 α /CXCR4-mediated migration of CSCs. However, the role of SDF-1 α /CXCR4 pathway in CSCs migration needs to be further clarified.

Phosphatidylinositol 3-kinase (PI3K) is widely expressed and plays crucial roles in regulating multiple cell processes, such as cell migration, proliferation, differentiation, motility, survival and angiogenesis [18–20]. There are two distinct activities that PI3K participates in, phosphorylation of the regulatory subunit by the

catalytic subunit and lipid phosphorylation. PI3K facilitates the transformation of phosphatidylinositol-3, 4-bisphosphate (PIP₂) into phosphatidylinositol-3, 4, 5-trisphosphate (PIP₃) which retrieves pleckstrin homology (PH) domain-containing proteins such as Akt to the cell membrane. Previous studies have demonstrated PI3K is also involved in SDF-1 α /CXCR4-mediated chemotaxis and multiple stem/progenitor cells migration [18,19,21]. Overexpression of VEGF resulted in CSCs migration and homing to the injured myocardium, which was inhibited by the PI3K/Akt inhibitor [17].

The purpose of this study was to address the following questions: 1) whether overexpression of SDF-1 α resulted in CSCs migration and accumulation in the infarcted region, and 2) whether SDF-1 α -induced CSCs migration was mediated via CXCR4/PI3K signaling pathway.

Materials and Methods

Ethics statement

Animal experiments were approved by the Institutional Animal Care and Use Committee of Third Military Medical University. All the procedures were in compliance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23).

Isolation and culture of c-kit⁺ CSCs

C-kit⁺ cardiac stem cells were isolated from neonatal Bab/c mice (3–5 d) according to previous methods [2,3,22,23]. Briefly, mouse hearts were removed and minced into small pieces, washed with phosphate buffered solution (PBS) and digested 3 times for 5 min at 37°C with a mixture of 0.2% trypsin (Invitrogen) and 0.1% collagenase IV (Sigma). Cells were filtered through 80- μ m mesh and the remaining tissue fragments were washed with PBS and cultured as explants in complete explant medium (CEM) [IMDM(HyClone) supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 Units/ml penicillin G, 100 μ g/ml streptomycin, 2 mmol/L L-glutamine (Invitrogen) and 0.1 mmol/L 2-Mercaptoethanol (Sigma)] at 37°C and 5% CO₂.

After 10 to 20 days, a layer of small, phasebright cells above the adherent explants were collected by washing with 0.5 g/L Trypsin-0.53 mmol/L EDTA. The cell suspension was filtered through a 40- μ m cell strainer and isolated by magnetic cell sorting (MACS, Miltenyi Biotec) using anti-c-kit-coupled magnetic beads (Miltenyi Biotec).

The purified c-kit⁺ cells were seeded at 0.5–2 \times 10⁵/ml in multiwell plates precoated with fibronectin in CGM(cardiosphere-growing medium) with minor modification [2,23] [Dulbecco's MEM and Ham's F12 (ratio 1:1, HyClone), 10% FBS, basic fibroblast growth factor (bFGF, 10 ng/ml, Invitrogen), epidermal growth factor (EGF, 20 ng/ml, Peperotech Inc), B27 (Invitrogen), thrombin (40 nmol/L, Sigma), LIF (1000 U/ml, Millipore), insulin–transferrin–selenite (Sigma), penicillin–streptomycin as in CEM] at 37°C and 5% CO₂.

Flow cytometric analysis

Cells phenotypes were analyzed by fluorescence-activated cell sorting (FACS). For this purpose, purified c-kit⁺ cells were co-incubated for 30 min in the dark at room temperature with the following antibodies: phycoerythrin (PE)-conjugated antibodies against CXCR4, Sca-1 or CD45 (from BD Biosciences), and FITC-conjugated antibodies against c-kit. PE- or FITC-conjugated isotype IgG were used as control. 10,000 to 50,000 cells were collected and subjected to flow cytometry using BD LSRII flow cytometer (BD Biosciences).

Multiple differentiation of c-kit⁺ cells [23]

The purified c-kit⁺ CSCs were identified by immunofluorescence using a monoclonal antibody for c-kit. To induce *in vitro* differentiation [3], c-kit⁺ cells were seeded on 35-mm dishes (5 \times 10⁴/dish) in DMEM [supplement with 10% FBS, 1 μ M dexamethasone (Sigma), 50 μ g/mL ascorbic acid (Sigma) and 1 mM β -glycerophosphate (Sigma)]. The medium was changed twice a week. Immunofluorescence analysis was performed with primary antibodies specific for cardiac troponin I (cTn-I) (1:200, Santa Cruz), α smooth muscle actin (α -SMA) (1:200, Zymed Lab) and von Willebrand factor (vWF) (1:200, BD PharMingen). Goat anti-rabbit second antibody conjugated with FITC and TRITC were used for immunocytochemistry staining. Staining was observed by a Leica fluorescence microscopy (TCS SP5, Leica).

rAAV1-SDF-1 α -eGFP vector construction

Vector production, harvest, purification and testing were carried out as previously described [24]. The 267 bp mouse SDF-1 α cDNA fragments combining with 3 bp stop codons were synthesized and amplified through polymerase chain reaction (PCR), inserted into the cloning sites between SalI and Bgl II in plasmid pSNAV2.0-mCMV-eGFP to construct the recombinant expression plasmid pSNAV2.0-SDF-1 α -eGFP. The recombinant plasmid pSNAV2.0-SDF-1 α -eGFP was co-transfected into HEK293 cells with the control plasmid pAAV-R2C1 and pHelper in AAV Helper-Free System for packaging of recombinant AAV. The efficiency of rAAV packaging was monitored under fluorescent microscope and recombinant viral particles were harvested from infected 293 cells. Viral titers were determined by dot blot analysis of DNA content and expressed as genome copies (gcs).

Primary culture of neonatal mouse cardiomyocytes and rAAV infection

Neonatal mouse cardiomyocytes were isolated from 3–4 day Bab/c mice by adherence separation method [4]. Hearts were minced and digested at 37°C in 0.125% trypsinase and 0.08% collagenase II (sigma). Isolated cells were suspended in DMEM-L comprising 20% FBS, HEPES, L-glutamine and antibiotics. After 2 hours of adherence, cell suspensions were seeded in 24-well plates at a density of 1 \times 10⁵ cells per well in a humidified condition. Two days later, the cardiomyocytes were infected with rAAV1-SDF-1 α -eGFP at a MOI of 10⁴.

Migration analysis

The migration of c-kit⁺ CSCs was assessed using 24-well transwell with an 8- μ m pore size (Millipore) [25]. Cardiac myocytes were seeded on lower chamber and infected with rAAV1-SDF-1 α -eGFP (infection group). Control group was infected with empty vector rAAV1-eGFP. Three days later, 5 \times 10⁴ c-kit⁺ CSCs were added into the upper chamber. Migrated cells were stained with DAPI (Invitrogen) and counted in 10 high-power microscopic fields 24 hours later. For inhibition experiments, CSCs were pre-incubated with AMD3100 (10 μ g/ml, Sigma–Aldrich) or LY294002 (20 μ mol/L, Beyotime) for 1 h before seeding.

The SDF-1 α protein concentration in lower chamber supernatant was determined by ELISA assay (R&D Systems) according to the manufacturer's instruction.

Myocardial infarction model, CSCs and rAAV vectors injection

Mice were anesthetized by 1% pentobarbital (50 mg/kg, i.p.) and the left anterior descending coronary artery (LAD) was ligated by the 8-0 nonabsorbable surgical suture [26]. Myocardial infarction was verified by color change in the ischemic area.

The mice were then divided into 6 groups: 1. Sham group: the mice chest was opened but without LAD ligation. 2. MI group: ligation of LAD but without other treatment. 3. Control (Empty) group: 50 μ l empty vector and 1×10^5 DAPI-labeled c-kit+ CSCs in 50 μ l saline were injected into infarcted zone and infarcted border individually, with a 30 G needle at four points. 4. SDF-1 α group: 50 μ l rAAV1-SDF-1 α -eGFP (2.25×10^{12} gcs/ml) and 1×10^5 DAPI-labeled c-kit+ CSCs were injected in similar way. 5. AMD3100 group: 50 μ l rAAV1-SDF-1 α -eGFP injection and 1×10^5 DAPI-labeled c-kit+ CSCs transplantation, however, pre-incubated with AMD3100 (10 μ g/ml) for 1 hour. 6. LY294002 group: 50 μ l rAAV1-SDF-1 α -eGFP injection and 1×10^5 DAPI-labeled c-kit+ CSCs transplantation, however, pre-incubation with LY294002 (20 μ mol/L) for 1 hour.

The infection efficiency was evaluated by detection of GFP expression under confocal fluorescent microscope at day 21 and detection of SDF-1 α expression by western blot respectively at day 0, 4, 7, 14, and 21.

Assessment of CSCs engraftment

To detect the engraftment of CSCs *in vivo*, 1×10^5 DAPI-labeled c-kit+ CSCs in 50 μ l saline were injected into infarcted border with a 30 G needle after coronary ligation. Three weeks after ligation, immunofluorescence was performed in infarcted regions to detect the engraftment of DAPI-labeled cells. *In vivo* differentiation of CSCs was tested by immunohistochemistry using cTn-I antibody [27]. Ten confocal images were counted for engraftment and differentiation assay.

Proliferation analysis of transplanted c-kit+ CSCs

Before being transplanted, c-kit+ CSCs were incubated with BrdU for 24 hours. Myocardial infarction model, rAAV-SDF-1 α -eGFP injection and CSCs transplantation were operated as above. Three weeks later, BrdU was detected by immunofluorescent using a monoclonal antibody in border zones and infarcted region. The proliferation percentage of transplanted c-kit+ CSCs was calculated as the percentage of BrdU-positive nuclei vs total DAPI-stained nuclei.

Infarcted size measurement

At day 21 post-MI, the infarcted size was measured by triphenyltetrazolium chloride (TTC) staining (n = 6) [28]. Briefly, the hearts were sliced transversely from the apex to base into 5 sections. Then, they were incubated for 30 min in 2% TTC (Sigma) solution at 37°C and fixed in 4% paraformaldehyde overnight. The infarcted myocardium (negative for TTC staining, white) and the non-ischemic zones (stained brick red) were divided and weighed. The infarction proportion was counted by ratio of infarcted mass/total heart.

Western blotting

The expression of SDF-1 α in infected zone was determined by western blot in 3 weeks. The mean densities of the bands were represented as the OD in units per square millimeter and normalized by GAPDH. The ratio of OD value of each group with control group served as the intensity of SDF-1 α expression.

Statistics

The data were analyzed using the SPSS 15.0 software. Continuous variables were expressed as mean \pm SD. Multiple groups comparison was performed by one-way ANOVA followed by the Bonferroni procedure for comparison of means. A value of $p < 0.05$ was considered significant.

Results

Culture of explants and c-kit+ CSCs

Five days after the heart tissues culture, fibroblasts migrated from the adherent explants. Then, some small, round and phase-bright cells appeared (Fig. 1A). After c-kit+ MACS isolation, these c-kit+ positive cells (green, Fig. 1B) were seeded in CGM and gradually formed three-dimensional spheres in 2 weeks (Fig. 1C).

Multipotent differentiation of c-kit+ CSCs

C-kit+ cells changed their shape in conditioned culture. Confocal immunofluorescence analysis showed expression of cTn-I (green, Fig. 1D), cardiomyocyte specific protein, α -SMA (red, Fig. 1E), smooth muscle specific marker, and the endothelial specific marker-vWF (red, Fig. 1F).

Flow cytometry analysis of cell surface markers

FACS of CD45, Sca-1 and CXCR4 co-stained with FITC-conjugated c-kit before MACS isolation were shown in Figure S1. However, 97% cells were c-kit positive after MACS isolation, and a few c-kit+ cells expressed CD45 ($4.54 \pm 1.79\%$, Fig. 1G) and Sca-1 ($2.58 \pm 1.16\%$, Fig. 1H), the marker of hematopoietic stem cells, indicating non-hematopoietic origin. Furthermore, we found high expression of CXCR4 ($91.47 \pm 7.73\%$, Fig. 1I), the receptor of SDF-1 α , in purified c-kit+ CSCs (n = 3). Controls with appropriate isotypes were shown in Fig. 1J, K and L respectively.

SDF-1 α /CXCR4 induced CSCs migration via PI3K pathway

The determinations of recombinant plasmid pSNAV2.0-SDF-1 α -eGFP and recombinated AAV1-SDF-1 α -eGFP are shown in Supplementary Material S1. rAAV1-SDF-1 α -eGFP construction was verified by PCR and immunofluorescence after infection (Figure S2). Three days after infection, over 90% cardiomyocytes expressed GFP and SDF-1 α . (Figure S2).

ELISA assay indicated that significant higher SDF-1 α concentration in infection group than control group (10.27 ± 1.8 ng/ml vs. 2.23 ± 0.67 ng/ml, $p < 0.01$, n = 3). Also, there was no difference among SDF-1 α , AMD3100 and LY294002 group (10.27 ± 1.7 ng/ml vs. 10.97 ± 1.8 ng/ml and 9.67 ± 2.2 ng/ml, $p > 0.05$, n = 3) (Fig. 2A). Overexpression of SDF-1 α attracted more c-kit+ CSCs migration (infection vs. control group, 48.3 ± 7.6 vs. 21.3 ± 6.1 , $p < 0.01$). This effect was diminished by AMD3100 (29.7 ± 6.0 vs. 48.3 ± 7.6 , $p < 0.05$) and LY294002 (26.0 ± 5.6 vs. 48.3 ± 7.6 , $p < 0.05$) incubation (Fig. 2B).

SDF-1 α /CXCR4 induced CSCs engraftment via PI3K pathway

The efficiency of *in vivo* rAAV1-SDF-1 α -eGFP infection is shown in Supplementary Material S1. Confocal fluorescence microscopy showed GFP expression in injected area (Figure S3A), indicating successful infection of rAAV1-eGFP and rAAV1-SDF-1 α -eGFP. Also, SDF-1 α expression peaked at day 14 and remained 2-fold elevated at day 21. (Figure S3B)

Western blot revealed that there was no difference of SDF-1 α expression between MI and Empty group. However, infection with rAAV1-SDF-1 α -eGFP significantly increased SDF-1 α




Figure 1. Culture and characterization of c-kit+ CSCs. A. small, round, phase-bright cells appeared. B. Purified c-kit+ cells were positive for c-kit staining (green). C. Phase-bright cells formed three-dimensional spheres. Multiple differentiation of c-kit+ cells into cardiomyocyte (D, green) smooth muscle (E, red), and endothelial cells (F, red). DAPI stained nuclei (blue). FACS analysis of c-kit+ cells phenotype with CD45 ($4.54\pm 1.79\%$, G), Sca-1 ($2.58\pm 1.16\%$, H) and CXCR4 ($91.47\pm 7.73\%$, I) ($n=3$). doi:10.1371/journal.pone.0043922.g001

expression in infarcted myocardium (SDF-1 α vs. MI, 2.22 ± 0.38 vs. 1.20 ± 0.19 , $p<0.01$, SDF-1 α vs. Empty, 2.22 ± 0.38 vs. 1.30 ± 0.17 , $p<0.01$) at day 21. There was no difference among SDF-1 α , AMD3100 and LY294002 groups (2.22 ± 0.38 vs. 2.08 ± 0.25 and 2.02 ± 0.31 , $p>0.05$, $n=3$) (Fig. 3A).

Immunofluorescence staining showed more CSCs in the infarcted regions in SDF-1 α group (SDF-1 α vs. Empty, 30.3 ± 6.5 vs. 10.3 ± 2.5 , $p<0.01$, $n=6$). However, the number of CSCs decreased in AMD3100 (AMD3100 vs. SDF-1 α , 8.7 ± 1.5 vs. 30.3 ± 6.5 , $p<0.01$) and LY294002 group (LY294002 vs. SDF-1 α , 8.0 ± 2.0 vs. 30.3 ± 6.5 , $p<0.01$) (Fig. 3B).

Proliferation and differentiation of transplanted CSCs

Proliferation of transplanted CSCs was determined by BrdU/DAPI double staining. Immunofluorescence staining showed more BrdU positive cells in the infarcted regions in SDF-1 α group than Empty group (SDF-1 α vs. Empty, 28.8 ± 1.5 vs. 8.9 ± 1.8 , $p<0.01$

$n=6$) (Fig. 4). However, the cells number decreased in AMD3100 (7.7 ± 1.7 , $p<0.01$ vs. SDF-1 α) and LY294002 group (7.9 ± 0.9 , $p<0.01$ vs. SDF-1 α). Furthermore, more proliferated cells were detected in infarcted region in SDF-1 α group than border zone ($p<0.05$) which contribute to the smaller infarcted area. There was no difference in border zone among all the groups.

To identify differentiation of CSCs, cTn-I staining was performed (Figure 5, red). Immunofluorescence staining showed more DAPI-labeled cells around high density of green fluorescence which confirmed that overexpression of SDF-1 α induced CSCs migration. Furthermore, we found that some DAPI-labeled CSCs were positive for cTn-I (red), indicating differentiation of homing CSCs into cardiomyocytes. Evidence for formation of novel myocytes was detected by the double positive of cTn-I and DAPI. However, we found that there was no difference of CSCs differentiation percentage among 4 groups in infarcted zone.




Figure 2. SDF-1 α /CXCR4 induced CSCs migration via PI3K pathway. A. rAAV1-SDF-1 α -eGFP infection increased SDF-1 α concentration in supernatant. * p <0.01 vs. control. n =3. B. SDF-1 α -induced CSCs migration was inhibited by AMD3100 and LY294002. * p <0.01 vs. control. # p <0.05 vs. infection group. Data were shown as mean \pm SD. n =3. doi:10.1371/journal.pone.0043922.g002

SDF-1 α /CXCR4 reduced MI size via PI3K pathway

TTC staining revealed empty vector infection didn't improve infarcted size (Empty vs. MI group, 30.0 \pm 4.0% vs. 27.3 \pm 3.2%, p >0.05, n =6). However, rAAV-SDF-1 α injection resulted in reduced infarcted size (SDF-1 α vs. MI group, 17.3 \pm 2.5% vs. 27.3 \pm 3.2%, p <0.05, n =6). This effect was abolished by AMD3100 pretreatment (SDF-1 α vs. AMD3100 group, 17.3 \pm 2.5% vs. 24.0 \pm 3.0%, p <0.05, n =6) and LY294002 pretreatment (SDF-1 α vs. LY294002 group, 17.3 \pm 2.5% vs. 25.3 \pm 3.1%, p <0.05, n =6) (Fig. 6).

Discussion

Cardiac myocytes have been traditionally regarded as terminally differentiated cells that can be adapted to increased work and compensate for disease exclusively through hypertrophy [1–3]. In the past few years, compelling evidence proves that the heart has regenerative potential [1,22]. Several types of CSCs have been recently identified according to the expression of some stem cell-related antigens including c-kit, MDR1, side population, Sca-1, Flk-1 or islet-1 [3,9,23,29]. *In vitro* data have suggested that c-kit+ CSCs have a stronger growth potential than other types, although all of these CSCs categories can give rise to all cardiac cell lineages [9]. Recently, initial results of a randomized phase 1 trial [11] suggested intracoronary infusion of autologous c-kit+ CSCs was effective in improving LV systolic function and reducing infarcted size after myocardial infarction, thus, demonstrating that c-kit+ CSCs might be a perspective candidate for MI therapy.

Because there are no adequate resident CSCs to replace injured heart issue after MI [4,10,23,29,30], it is crucial to purify and expand CSCs *in vitro* for cardiac repair. We showed that c-kit+ cells

kept their capacity for self-renewal and clonogenic *in vitro* with CGM medium, and could differentiate into cardiomyocytes, endothelial cells and smooth muscle cells. FACS analysis showed that they were not hematopoietic stem cells.

SDF-1 α is a member of the CXC or a chemokine subfamily and the only known ligand for the chemokine receptor CXCR4 [19]. SDF-1 α is constitutively expressed in a large number of tissues and plays an important role in multiple stem cells migration by binding CXCR4 [5,16,17,19,25]. Yu et al reported that MI in rat hearts led to an increased expression of SDF-1 α , which mediated migration of BMSCs through SDF-1 α /CXCR4 and activation of PI3K/Akt [18]. However, the role of SDF-1 α /CXCR4 pathway in CSCs migration is still needed to be further clarified. *a et al* reported SDF-1 α expression was significantly higher within 4 days post operation in the MI groups and peaked at 1 day post MI [31]. In our present study, we did not observed a high expression of SDF-1 α in the Empty and MI groups at day 21 after MI which might be due to the death of infarcted myocardium. Also, previous study found that myocardial infarction increased expression of SDF-1 α mRNA by 56.7% and 95.7% at 48 and 72 hours, respectively, and returned to baseline by 7 days. SDF-1 α protein level peaked at 72 hours and remained 2-fold elevated at 96 hours [32]. Thus, the SDF-1 α expression in infarcted zone decreased rapidly and it is reasonable that endogenous SDF-1 α is not sufficient for CSCs engraftment and myocardial repair in chronic phase-a suitable time for stem cells survival after acute inflammatory response. Recently, Tang et al [33] reported that exogenously expressed VEGF promoted myocardial repair at least in part through SDF-1 α /CXCR4-mediated recruitment of CSCs. Considering of rare CSCs in the heart, we focused on the effect of CSCs transplantation in combination with exogenously





A SDF-1 α Expression of Infarct Zone**B SDF-1 α Induced CSCs homing**

Figure 3. SDF-1 α /CXCR4 induced CSCs homing via PI3K pathway. **A.** Western blotting analysis of SDF-1 α expression in the infarcted zone 3 weeks after coronary artery ligation or sham operation (the ratio of SDF-1 α expression vs. Sham group). * $p < 0.05$ vs. Sham, MI and Empty (vector) group. GAPDH served as an internal control. Data were shown as mean \pm SD. $n = 3$. **B.** SDF-1 α induced the CSCs Homing. Overexpression of SDF-1 α induced DAPI-labeled CSCs homing to the infarcted zone. This effect was inhibited by AMD3100 and LY294002 pretreatment. * $p < 0.01$ vs. Empty, AMD (AMD3100) and LY (LY294002) group. Results were shown as mean \pm SD, $n = 6$. doi:10.1371/journal.pone.0043922.g003

overexpression of SDF-1 α in chronic phase after MI, which might be better associated with clinical feasibility.

Our result suggests that SDF-1 α overexpression *in vivo* could promote the engraftment of the locally transplanted CSCs into the infarcted region and cardiac repair. Blocking CXCR4 with AMD3100 can eliminate these effects, indicating an essential role of SDF-1 α /CXCR4 axis in CSCs migration and recruitment. CXCR4 is a Gi-coupled receptor. Studies have shown that SDF-1 α , after binding to CXCR4, causes mobilization of calcium, decreases of cyclic AMP within the cells, and activates multiple signaling pathways such as PI3K [34]. The activation of the PI3K-Akt pathway can occur as a result of G-protein-coupled receptor triggering- through direct interaction with the active G protein $\beta\gamma$ subunit, or indirectly, by α subunit-induced tyrosine kinase activity [35]. PI3K catalyzes the phosphorylation of membrane phosphatidylinositols generating phosphatidylinositol mono-, bis-, and tris-phosphate [36]. These products recruit the protein kinase Akt by interacting with its PH domain and facilitate its phosphorylation on threonine 308 and serine 473 by phosphoinositide-dependent kinase 1 and 2 [37]. Ultimately, SDF-1 α -bound CXCR4 induces cytoskeletal rearrangement, adhesion to endothelial cells, polarized migration of cells to specific organs and the secretion of

angiopoietic factors, all important components of the repair process [38,39].

Although previous experiment has provided direct evidence that the PI3K pathway is required for SDF-1 α -induced cell migration in HPC, BMSC [16,18] and VEGF-induced CSCs migration [17], there are no related report involving SDF-1 α action on CSCs. We found that administration of the specific PI3K inhibitor LY294002 significantly inhibited the SDF-1 α -induced CSCs migration and engraftment, indicating the important role of PI3K pathway. Furthermore, as a known downstream effector of the PI3K dependent signaling cascade, Akt is required for SDF-1 α -mediated chemotaxis, cell proliferation and regulation of integrin [18,19,40] and thus may play a role in SDF-1 α /CXCR4 mediated CSCs migration and recruitment.

In addition to CSCs, stem cells and/or progenitors from the bone marrow, such as mesenchymal stem cells (MSCs) [18], hematopoietic stem cells (HSCs), and endothelial progenitor cells (EPCs) [16,19], may be recruited to participate in the repair process of ischemic myocardium through SDF-1 α /CXCR4 axis. Thus, the beneficial effects of SDF-1 α overexpression on myogenesis and angiogenesis in the ischemic heart, as demonstrated in our experiments, may also involve these cells from extracardiac sources.




Figure 4. Proliferation of transplanted CSCs. **A.** proliferation of transplanted CSCs was determined by BrdU and DAPI double staining (red and blue) 3 weeks after myocardial infarction. Scale bar = 10 μ m. **B.** Quantitative analysis of the ratio of BrdU/DAPI double positive cells. Data were shown as mean \pm SD. * $P < 0.01$ vs. Empty, AMD and LY group in infarcted zone. $n = 6$. doi:10.1371/journal.pone.0043922.g004




Figure 5. Differentiation of transplanted CSCs in infarcted zone. **A.** differentiation of transplanted CSCs was determined by cTn-I and DAPI double staining (red and blue) 3 weeks after myocardial infarction. Scale bar = 10 μ m. **B.** Quantitative analysis of the ratio of cTn-I/DAPI double positive cells. Data were shown as mean \pm SD. $n = 6$. doi:10.1371/journal.pone.0043922.g005




Figure 6. SDF-1 α /CXCR4 reduced MI size via PI3K pathway. **A.** representative pictures of TTC-stained heart sections. (white, necrotic regions, not stained red by TTC). **B** graphic representation of the infarct size expressed as mass percentage of infarct size/total heart. *, $P < 0.05$ vs. MI group, #, $P < 0.05$ vs. SDF-1 α group, $n = 6$. doi:10.1371/journal.pone.0043922.g006

We also detected the fate of transplanted CSCs 3 weeks after MI. Although there was no difference of differentiated CSCs among 4 groups in infarcted area, more proliferated CSCs in infarcted zone in SDF-1 α group were disclosed than other groups. It could be the reason of improved infarcted size after SDF-1 α overexpression.

In conclusion, the present study showed that overexpression of SDF-1 α induced CSCs migration *in vitro* and engraftment of transplanted CSCs and reduced infarcted size via CXCR4/PI3K pathway which representing a novel therapeutic strategy for MI.

Supporting Information

Figure S1 FACS of cultured cells before c-kit MACS isolation.

(TIF)

Figure S2 Determination of rAAV1-SDF-1 α -eGFP.

(TIF)

References

- Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, et al. (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* 114: 763–776.
- Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, et al. (2004) Isolation and expansion of adult cardiac stem cells from human and murine heart. *Circ Res* 95: 911–921.
- Miyamoto S, Kawaguchi N, Ellison GM, Matsuoka R, Shin'oka T, et al. (2010) Characterization of long-term cultured c-kit⁺ cardiac stem cells derived from adult rat hearts. *Stem Cells Dev* 19: 105–116.
- Koninckx R, Daniels A, Windmolders S, Carlotti F, Mees U, et al. (2011) Mesenchymal stem cells or cardiac progenitors for cardiac repair? A comparative study. *Cell Mol Life Sci* 68: 2141–2156.
- Theiss HD, Vallaster M, Rischpler C, Krieg L, Zaruba MM, et al. (2011) Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. *Stem Cell Res* 7: 244–255.
- Fischer KM, Din S, Gude N, Konstantin MH, Wu W, et al. (2011) Cardiac progenitor cell commitment is inhibited by nuclear Akt expression. *Circ Res* 108: 960–970.
- Carr CA, Stuckey DJ, Tan JJ, Tan SC, Gomes RS, et al. (2011) Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks—an MRI study. *PLoS One* 6: e25669.
- Frati C, Savi M, Graiani G, Lagrasta C, Cavalli S, et al. (2011) Resident cardiac stem cells. *Curr Pharm Des* 17: 3252–3257.
- Li M, Naqvi N, Yahiro E, Liu K, Powell PC, et al. (2008) c-kit is required for cardiomyocyte terminal differentiation. *Circ Res* 102: 677–685.
- Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, et al. (2010) Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. *Circulation* 121: 293–305.
- Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, et al. (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet* 378: 1847–1857.

Figure S3 The efficiency of *in vivo* rAAV1-SDF-1 α -eGFP infection.

(TIF)

Supplementary Material S1 Supplementary methods and results.

(DOC)

Acknowledgments

The authors thank Prof. Jihang Zhang for later revision and Huali Kang for technical assistance.

Author Contributions

Conceived and designed the experiments: LH XZ KW. Performed the experiments: KW CK DQ HW HJ MD. Analyzed the data: KW. Contributed reagents/materials/analysis tools: XZ KW MD. Wrote the paper: KW XZ.

12. Li Q, Guo Y, Ou Q, Chen N, Wu WJ, et al. (2011) Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models. *Basic Res Cardiol* 106: 849–864.
13. Guo HD, Wang HJ, Tan YZ, Wu JH (2011) Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction. *Tissue Eng Part A* 17: 45–58.
14. Zakharova L, Mastroianni D, Mutlu N, Molina M, Goldman S, et al. (2010) Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. *Cardiovasc Res* 87: 40–49.
15. Ellison GM, Torella D, Dellegrattaglia S, Perez-Martinez C, Perez de Prado A, et al. (2011) Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. *J Am Coll Cardiol* 58: 977–986.
16. Zhao X, Huang L, Yin Y, Fang Y, Zhao J, et al. (2008) Estrogen induces endothelial progenitor cells proliferation and migration by estrogen receptors and PI3K-dependent pathways. *Microvasc Res* 75: 45–52.
17. Tang J, Wang J, Kong X, Yang J, Guo L, et al. (2009) Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway. *Exp Cell Res* 315: 3521–3531.
18. Yu J, Li M, Qu Z, Yan D, Li D, et al. (2010) SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal cells toward areas of heart myocardial infarction through activation of PI3K/Akt. *J Cardiovasc Pharmacol* 55: 496–505.
19. Zheng H, Fu G, Dai T, Huang H (2007) Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1 α /CXCR4 via PI3K/Akt/eNOS signal transduction pathway. *J Cardiovasc Pharmacol* 50: 274–280.
20. Wang H, Yin Y, Li W, Zhao X, Yu Y, et al. (2012) Over-expression of PDGFR- β promotes PDGF-induced proliferation, migration, and angiogenesis of EPCs through PI3K/Akt signaling pathway. *PLoS One* 7: e30503.
21. Fruman DA, Meyers RE, Cantley LC (1998) Phosphoinositide kinases. *Annu Rev Biochem* 67: 481–507.
22. Bearzi C, Rota M, Hosoda T, Tillmanns J, Nascimbene A, et al. (2007) Human cardiac stem cells. *Proc Natl Acad Sci U S A* 104: 14068–14073.
23. Tang YL, Shen L, Qian K, Phillips MI (2007) A novel two-step procedure to expand cardiac Sca-1+ cells clonally. *Biochem Biophys Res Commun* 359: 877–883.
24. Andino LM, Takeda M, Kasahara H, Jakymiw A, Byrne BJ, et al. (2008) AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. *J Gene Med* 10: 132–142.
25. Huang PH, Chen YH, Tsai HY, Chen JS, Wu TC, et al. (2010) Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. *Arterioscler Thromb Vasc Biol* 30: 869–877.
26. Takamiya M, Haider KH, Ashraf M (2011) Identification and characterization of a novel multipotent sub-population of Sca-1 cardiac progenitor cells for myocardial regeneration. *PLoS One* 6: e25265.
27. Kuang D, Zhao X, Xiao G, Ni J, Feng Y, et al. (2008) Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK. *Basic Res Cardiol* 103: 265–273.
28. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, et al. (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. *Circ Res* 107: 1445–1453.
29. Barile L, Messina E, Giacomello A, Marban E (2007) Endogenous cardiac stem cells. *Prog Cardiovasc Dis* 50: 31–48.
30. Segers VF, Lee RT (2008) Stem-cell therapy for cardiac disease. *Nature* 451: 937–942.
31. Ma J, Ge J, Zhang S, Sun A, Shen J, et al. (2005) Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. *Basic Res Cardiol* 100: 217–223.
32. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, et al. (2004) Stromal cell-derived factor-1 α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. *Circulation* 110: 3300–3305.
33. Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, et al. (2011) VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. *Cardiovasc Res* 91: 402–411.
34. Sotsios Y, Whittaker GC, Westwick J, Ward SG (1999) The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes. *J Immunol* 163: 5954–5963.
35. Vanhaesebroeck B, Leever SJ, Ahmadi K, Timms J, Katso R, et al. (2001) Synthesis and function of 3-phosphorylated inositol lipids. *Annu Rev Biochem* 70: 535–602.
36. Rameh LE, Cantley LC (1999) The role of phosphoinositide 3-kinase lipid products in cell function. *J Biol Chem* 274: 8347–8350.
37. Downward J (1998) Lipid-regulated kinases: some common themes at last. *Science* 279: 673–674.
38. Hillyer P, Mordet E, Flynn G, Male D (2003) Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration. *Clin Exp Immunol* 134: 431–441.
39. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, et al. (2007) Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. *Blood* 109: 2708–2717.
40. Zheng H, Shen CJ, Qiu FY, Zhao YB, Fu GS (2010) Stromal cell-derived factor 1 α reduces senescence of endothelial progenitor subpopulation in lectin-binding and DiLDL-uptaking cell through telomerase activation and telomere elongation. *J Cell Physiol* 223: 757–763.